Business Context and Reporting Period
This Form 8-K filing by AnaptysBio, Inc. (ANAB) reports a corporate governance event dated September 24, 2019. The company is incorporated in Delaware and trades on the Nasdaq Global Market.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a board appointment and associated compensation.
Material Changes
The primary material change reported is the appointment of Laura Hamill as a Class II director on the Board of Directors, effective September 24, 2019.
Management Commentary and Compensation Details
- Appointment: Laura Hamill was appointed as a non-employee director.
- Compensation Grant 1 (Pro Rata Retainer): Ms. Hamill received a stock option to purchase 2,268 shares of common stock. The exercise price equals the closing sale price on September 24, 2019. Vesting occurs monthly: 1/4th on November 8, 2019, and 1/4th each month thereafter.
- Compensation Grant 2 (Annual Retainer): Ms. Hamill received a stock option to purchase 6,000 shares of common stock. The exercise price equals the closing sale price on September 24, 2019. Vesting occurs monthly over three years, contingent on continued service.
- Indemnification: The Company entered into its standard form of indemnification agreement with Ms. Hamill.
- Relationships: No family relationships exist between Ms. Hamill and other directors or officers, and no undisclosed arrangements influenced her selection.
Investor Verification Checklist
- Verify the closing stock price of ANAB on September 24, 2019, to determine the exercise price of the granted options.
- Review the Company's existing compensation policy for non-employee directors to confirm the pro rata calculation for the partial-year retainer.
- Confirm the total number of outstanding shares and the potential dilution impact of the 8,268 newly granted options.
- Check subsequent filings to confirm Ms. Hamill's continued service and the vesting schedule adherence.